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Introduction: Computational molecular database screening helps to decrease the time and 
resources needed for drug development. Reintroduction of generic drugs by second medical 
use patents also contributes to cheaper and faster drug development processes. We screened, 
in silico, the Food and Drug Administration-approved generic drug database by means of the 
One-dimensional Drug Profile Matching (oDPM) method in order to find potential peroxisome 
proliferator-activated receptor gamma (PPARγ) agonists. The PPARγ action of the selected 
generics was also investigated by in vitro and in vivo experiments.
Materials and methods: The in silico oDPM method was used to determine the binding 
potency of 1,255 generics to 149 proteins collected. In vitro PPARγ activation was determined 
by measuring fatty acid-binding protein 4/adipocyte protein gene expression in a Mono Mac 
6 cell line. The in vivo insulin sensitizing effect of the selected compound (nitazoxanide; 
50–200 mg/kg/day over 8 days; n = 8) was established in type 2 diabetic rats by hyperinsulinemic 
euglycemic glucose clamping.
Results: After examining the closest neighbors of each of the reference set’s members and 
counting their most abundant neighbors, ten generic drugs were selected with oDPM. Among 
them, four enhanced fatty acid-binding protein/adipocyte protein gene expression in the Mono 
Mac 6 cell line, but only bromfenac and nitazoxanide showed dose-dependent actions. Induction 
by nitazoxanide was higher than by bromfenac. Nitazoxanide lowered fasting blood glucose 
levels and improved insulin sensitivity in type 2 diabetic rats.
Conclusion: We demonstrated that the oDPM method can predict previously unknown thera-
peutic effects of generic drugs. Nitazoxanide can be the prototype chemical structure of the 
new generation of insulin sensitizers.
Keywords: computer-aided prediction of receptor-ligand interaction, in silico lead selection, 
insulin sensitizers, one-dimensional drug profile matching, peroxisome proliferator activated 
receptor gamma, PPARγ, type two diabetes
Introduction
Drug development is a highly time-consuming and costly process that usually lasts for 
approximately 10–12 years and requires about 800–1,000 million US dollars.1 This 
huge amount of resources can be explained by the high attrition rate of drug candidates 
during the whole drug development process. In general, it can be estimated that only 
one out of every 50–100 candidates that enter into the preclinical research phase will 
finally reach the market; the remaining candidates will be abandoned during the pre-
clinical or clinical phase of the development process. This is why both society and the 
pharmaceutical industry have the drive to find methods to develop cheaper and more 
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effective drugs in the near future. Theoretically, there are 
several  possibilities to shorten the amount of time or decrease 
the total costs required for drug development. Every activity 
that can speed up the development process and reduce the 
time-to-market can bear significant advances. One possible, 
and perhaps the simplest, way to decrease the amount of 
resources needed for drug development is by repositioning 
generic drugs in new therapeutic indications, resulting in the 
so-called “second medical use” patents.
The reason for the high attrition rate among drug can-
didates originated from either their inefficacy at treating 
human pathological conditions or from its safety concerns, 
since the beneficial and adverse effects can occur over 
the long-lasting administration of drugs. In addition, drug 
 candidates are unpredictable based on the in vitro and in vivo 
test systems used to characterize the pharmacokinetic and 
pharmacodynamic properties of a drug candidate. During 
the last decade, the cost of drug development  significantly 
increased in  parallel with increasingly more rigorous 
 regulations. This resulted in the intention to develop drug 
candidates that – beside their improved efficacy – are 
proven to be safe. This led to the quest of establishing new 
methodologies to bring significant improvements in the 
predictability of the therapeutic and adverse effect profile of 
drug candidates. One possible approach is to use molecular 
docking methods to study the interaction between the drugs 
and their molecular targets.
Another, less widespread approach is the application of 
the docking results as virtual affinity fingerprints and using 
them as an interaction pattern (IP) that describes the gen-
eral interaction properties of a molecule. Here, the overall 
information contained in the pattern is used instead of the 
data that can be concluded from the individual interactions. 
Such a method is Drug Profile Matching (DPM), which aims 
to relate the medical effect profiles and target profiles of 
approximately 1,200 Food and Drug Administration (FDA)-
approved small-molecule drugs with their virtual affinity 
fingerprints (ie, a series of docking scores of the molecule 
against the ligand binding sites of a predefined set of 149 
proteins).2 The starting hypothesis behind DPM is that similar 
affinity fingerprints refer to similar bioactivity properties (ie, 
targets and medical effects). We found that there is a strong 
relationship between the 177 medical effects studied and 77 
target categories with the virtual affinity fingerprints of the 
drugs.3 Receiver operating characteristic analysis and cross-
validations proved that the method is robust, and the affin-
ity fingerprints provide enough information to recreate the 
effect profiles of drugs. In a following study, we studied the 
contribution of the structural features of the drugs to the high 
prediction power of the method. We showed that DPM outper-
formed conventional two-dimensional and three-dimensional 
structural similarity-based prediction approaches in almost all 
examined categories.4 Nevertheless, its prediction accuracy 
is limited if only a few compounds can be used as a learning 
set for a given effect. Apart from the already known effects, 
previously unrevealed bioactivities (medical effects, targets, 
and so on) can also be predicted for the existing drugs by 
this method. These predictions can be validated by in vitro/
in vivo tests or by retrospective literature analyses.
Although there are growing numbers of type 2 diabetic 
patients, the available remedy for this disease is confined 
to a limited number of drug classes. The most frequently 
prescribed medication for the treatment of type 2 diabetes 
is the group of thiazolidinediones.5 This class of drugs 
acts through the nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARγ), and its activation can be 
exploited to improve insulin sensitivity in insulin-resistant 
animals or humans.6 In spite of the fact that this class of drugs 
reached a blockbuster status shortly after it was introduced 
into the market, there are currently safety concerns regard-
ing all three representatives of thiazolidinediones. The first 
marketed thiazolidinedione, troglitazone (Rezulin®; Warner-
Lambert, Morris Plains, NJ, USA) was withdrawn from the 
market due to its hepatotoxicity.7 Rosiglitazone (Avandia®; 
 GlaxoSmithKline, London, UK) was withdrawn from the 
European market while it was put under selling restrictions 
in the USA due to its high incidence of cardiovascular events 
observed in connection with its administration.8 Finally, 
the sale of pioglitazone (Actos®; Takeda Pharmaceutical 
 Company Limited, Osaka, Japan) was suspended in the 
 German and France markets due to its potential effect to 
induce bladder cancer.9 On the other hand, these side effects 
do not seem to be class effects, which can encourage aca-
demic and industrial researchers to find a drug candidate 
with PPARγ receptor agonist activity that does not result in 
the abovementioned or other side effects.
The aim of the present study was to investigate whether 
our in silico prediction method could be used for screening 
generic drugs in order to find new therapeutic indications. 
To test our methodological approach, the FDA database 
containing 1,255 generic drugs was screened to predict their 
PPARγ activation propensities. Then, the in silico selected 
drugs were tested in vitro using PPARγ receptor-expressing 
cell cultures to determine whether they are able to activate 
the PPARγ receptor. Finally, a series of in vivo experiments 
were carried out by means of hyperinsulinemic euglycemic 
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glucose clamping (HEGC) in a rat model of type 2 diabe-
tes in order to study the PPARγ receptor-related insulin 
sensitizing effect of a drug showing the most promising in 
vitro effect.
Materials and methods
Ethical aspects
The study protocol was formally approved by the University 
of Debrecen Animal Ethics Committee (Debrecen, Hungary). 
The experiments presented conform to European  Community 
guiding principles for the care and use of laboratory  animals. 
The experimental protocols that were applied had been 
approved by the local ethical boards of the University of 
Debrecen, Debrecen, Hungary (08/2007 DEMÁB and 
16/2007 DEMÁB).
One-dimensional DPM
The selection of potential PPARγ antagonist candidates was 
performed using a simpler version of the recently introduced 
DPM – a systematic, pattern-based, bioactivity prediction 
method.2 This method uses virtual affinity fingerprints of 
small molecule compounds to predict their medical effects 
and targets.2,3 In DPM, the affinity fingerprint is called IP, 
which consists of a set of docking scores of a compound 
against the binding sites of a predefined nontarget protein 
set. The main difference between DPM and One-dimen-
sional DPM (oDPM) presented here  (Figure 1A) is that 
the latter method applies a one-dimensional distance-like 
metric to compare the IPs that were considered as vec-
tors in a multidimensional space, while DPM generates 
hyperplanes to separate active and inactive compounds in 
the multidimensional space. The main reason for applying 
oDPM instead of DPM includes the limited number of 
compounds in the reference set. In our earlier work, we 
found that at least ten members are required for a group to 
reliably perform multivariate statistical methods of DPM;2 
with under ten members, an alternative evaluation method 
is required, like oDPM. Since the detailed mechanism of 
DPM has been introduced earlier,3 we will only summarize 
its most important features and point to the differences 
between oDPM and DPM.
Data collection
A total of 1,255 FDA-approved drug molecules were 
extracted from the DrugBank database.10 In addition, 149 
proteins were collected from the Research Collaboratory for 
Structural Bioinformatics Protein Data Bank,11 as described 
in our previous work.2
Docking preparations and calculations
Docking preparations and calculations were performed by 
AutoDockTools12 (Molecular Graphics Laboratory, The 
Scripps Research Institute, La Jolla, CA, USA) and DOVIS 2.0 
(DOcking-based VIrtual Screening, Biotechnology High 
Performance Computing Software Applications Institute, 
Department of Defense, Frederick, MD, USA) software,13 
using the AutoDock4 (Molecular Graphics Laboratory, 
The Scripps Research Institute) docking engine with its 
native scoring function.14,15 Preparation procedures were the 
same as presented earlier.2 Each drug molecule was docked 
to each protein, and binding free energies were extracted and 
the minima were imported into a database. Docking runs 
were performed on a Hewlett-Packard cluster of 104 central 
processing units (Hewlett-Packard Company, Palo Alto, 
CA, USA). In sum, 1,255 × 149 = 186,995 dockings were 
 performed, repeated 200 times for each drug–protein pair, and 
were docked and scored by AutoDock4 (Molecular Graphics 
Laboratory, The Scripps Research Institute).
Reference set
Instead of using a medical effect database, a single-target 
focused reference set of eight molecules was applied. These 
known PPARγ antagonists were rosiglitazone, bexarotene, 
gemfibrozil, pioglitazone, alpha-linolenic acid, fenofibrate, 
bezafibrate, and clofibrate.
IP similarity calculations
A similarity coefficient (d) based on the angle enclosed by 
two IP vectors was used to create the IP similarity matrix. 
The IP vectors are determined by the docking scores as 
coordinates in a 149-dimensional space created by the 
149 members of the protein set. Cosine angle distance 
coefficient16 was used to determine the angle between two 
vectors in the above-described 149-dimensional space as 
follows:
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where d
AB
 is the IP distance value between molecules A and 
B, and a
i
 and b
i
 are the docking score values of molecules 
A and B on the i-th protein of n = 149, respectively.
Neighbor-based bioactivity prediction
Based on the IP similarity matrix, similarity lists were gener-
ated to each member of the reference set. Applying the cut-off 
Drug Design, Development and Therapy 2013:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
920
Kovács et al
value of d = 3, the number of appearances of the drugs on 
each list was calculated, and the most abundant compounds 
were selected for further analysis (Figure 1B). The maximum 
number of appearances was three.
In vitro study
The PPARγ-activating actions of the in silico-selected gener-
ics were tested on a Mono Mac 6 (MM6) cell line. The MM6 
is a monoblastic leukemic cell line, which is known to express 
PPARγ. The activation of PPARγ results in the expression of 
a wide range of genes; among them, some can be activated 
solely by the PPARγ. One of them is the fatty acid-binding 
protein 4/adipocyte protein (FABP4/aP2) gene,17 which was 
studied.
The study was carried out on 48-well plate, with 
200,000 cells per well. Every treatment was done in  triplicate. 
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Figure 1 Summary of the oDPM.
Notes: (A) Summary of the oDPM: IP generation and IP similarity calculations. Drugs A and X are docked to the 149 members of the protein set. Their respective IPs (with 
color-coded energy values ranging from green to red [ie, from lower DS to higher DS values, respectively]) are compared, and a pairwise similarity value is calculated. Based 
on these values, similarity lists are created for each drug, containing the remaining set of molecules in a decreasing order of similarity. (B) Summary of the effect prediction 
method using oDPM. In the first step, similarity lists are created for each drug in the reference set (containing eight compounds in this case) and cut at a predefined IP distance 
value (d). Then, drugs appearing multiple times in the truncated lists are collected. Reference drugs appearing in each other’s similarity lists are omitted. The remaining drugs 
are predicted to possess the given effect.
Abbreviations: DS, docking score; IP, interaction pattern; oDPM, One-dimensional Drug Profile Matching.
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The cells were pretreated with phorbol 12-myristate 13- 
acetate, which makes the cells similar to macrophages and 
sensitizes their PPARγ response. After 24 hours, the phor-
bol 12-myristate 13-acetate was washed out, fresh nutrient 
solution was added, and then the treatment was commenced 
by increasing the doses (10−8 M to 10−5 M) of the selected 
drugs in order to obtain their concentration–response curves. 
Rosiglitazone (10−8 M to 10−5 M) was used as a positive con-
trol, and the vehicle (dimethyl sulfoxide, ethanol, or water) as 
a negative control. After 24 hours of incubation, the cells were 
lysated in TRIzol® reagent (Life Technologies, Carlsbad, CA, 
USA), and the ribonucleic acid (RNA) was isolated. Then, 
the samples of RNA were converted into complementary 
deoxyribonucleic acid by means of reverse transcription 
polymerase chain reaction, and the PPARγ activity was deter-
mined by measuring the expression of the FABP4/aP2 gene’s 
messenger RNA (mRNA) by real-time reverse transcription 
polymerase chain reaction. Beside the FABP4/aP2 gene, the 
mRNA expression of the cyclophilin A housekeeping gene 
was also determined in the samples. Then, the data obtained 
from the FABP4/aP2 gene expression were normalized to 
the cyclophilin A values by means of the ∆∆Ct method, and 
these normalized values were evaluated.
Animals and study design
The experiments were carried out on 5-week-old male Wistar 
rats. The animals were housed in an animal room with a 
temperature of 22°C–24°C, and with 50%–70% relative 
humidity. The lighting was set to 12-hour light and 12-hour 
dark periods.
Forty-eight animals were used throughout the study, 
and they were divided into three main groups. The first 
main group of Wistar rats served as healthy, vehicle-treated 
 controls. These animals were held on a standard laboratory 
diet (ssniff®, EF R/M Control; ssniff Spezialdiäten GmbH, 
Soest, Germany), and they drank tap water ad libitum. The 
second main group of the rats was fed with a high-fat diet 
(HFD, ssniff®, EF R/M with 20% fat; ssniff Spezialdiäten 
GmbH, Soest, Germany) for 3 weeks. These rats served as 
the insulin-resistant, nondiabetic, vehicle treated group. In 
the first two main groups of rats, eight rats per group were 
used. The third main group of rats was divided into four 
subgroups with eight rats per subgroup. These rats were fed 
HFD for 2 weeks, and they were then treated with streptozo-
tocin (STZ; 50 mg/kg, intraperitoneally). After an additional 
week, the animals showed stable fasting hyperglycemia. This 
animal model mimics the two characteristic features of type 
2  diabetes. The peripheral insulin resistance was induced by 
the HFD, while impaired glucose-stimulated insulin secre-
tion was induced by the STZ treatment. This type 2 diabetic 
animal model was originally established and validated by 
Reed et al.18 The first subgroup of the third main group was 
treated with vehicle, and the remaining three subgroups 
were treated with a daily oral dose of 50 mg/kg, 100 mg/kg, 
and 200 mg/kg of nitazoxanide, respectively. All treatments 
lasted for 8 days, and the on the final day, 2 hours after the 
last vehicle/drug administration, the animals were anesthe-
tized in order to execute the HEGC study for determination 
of whole-body insulin sensitivity.
Dose selection
As our ultimate goal was to find a generic drug that could 
be reintroduced in new clinical indications, the important 
aspect of our drug development paradigm was that the 
drug could improve insulin sensitivity in similar or lower 
doses than previously used in animal studies, where the 
drug demonstrated its efficacy in the originally approved 
indication (such as nitazoxanide as an antiprotozoal agent). 
Accordingly, we selected doses of nitazoxanide where the 
dose range (50–200 mg/kg/day) demonstrated efficacy in 
reducing oocyst shedding in an immunosuppressed rat model 
of cryptosporidiosis.19
Determination of insulin sensitivity
The HEGC procedure was performed as described 
 previously.20 In brief, after an overnight fasting, rats 
were anesthetized with an intraperitoneal injection of 
50 mg/kg of sodium thiopental (Thiopental Sandoz®; Sandoz 
 Pharmaceutical PLC, Basel, Switzerland). After a middle 
sagittal surgical incision on the ventral surface of the neck, the 
trachea was exposed and a polyethylene tube was introduced 
into it to allow spontaneous breathing of the animals. Then, 
the left jugular vein and the left carotid artery were exposed 
and cleaned from the adhering connective tissues. Insulin and 
glucose were infused as separate lines of infusion through 
the two branches of the left jugular vein, while the arterial 
cannula served for blood pressure monitoring as well as to 
obtain blood samples (0.1 mL) for subsequent blood glucose 
and plasma insulin determinations. When the surgery was 
completed, there was a 30-minute stabilization period; then, 
a continuous insulin infusion (Humulin R®; Eli Lilly and 
Company, Indianapolis, IN, USA) at a rate of 3 mU/kg/minute 
was commenced along with glucose infusion (20% w/v). The 
rate of glucose infusion was adjusted in order to maintain 
euglycemia (5.5 ± 0.5 mmol/L). The blood glucose concentra-
tion was determined by means of a glucometer (Accu-Chek®; 
Drug Design, Development and Therapy 2013:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
922
Kovács et al
F Hoffmann La-Roche Ltd, Basel, Switzerland) before and 
at 5-minute intervals during the first 80 minutes, and at 
10-minute intervals during the last 40 minutes of the HEGC 
experiment. In order to determine the fasting and steady-state 
plasma levels of insulin, additional blood samples were col-
lected (0.5 mL, in 20 µL of ethylenediaminetetraacetic acid 
and 10 µL of Trasylol®; Bayer AG, Leverkusen, Germany) 
from the carotid artery immediately before the commence-
ment of insulin infusion and during the steady state of the 
HEGC, respectively. The blood samples were centrifuged 
(Centrifuge 5415R;  Eppendorf AG,  Hamburg, Germany) for 
2 minutes at 4°C and 10,000g; then, the plasma was aliquoted, 
frozen, and stored at −70°C for subsequent determinations. 
The plasma insulin level was determined by means of a 
commercially available radioimmunoassay kit (RK-400CT, 
Institute of Isotopes of the Hungarian Academy of Sciences, 
Budapest, Hungary). The average glucose infusion rate 
(GIR; mg/kg/minute) required to maintain the euglycemia 
during the last 30 minutes of the HEGC characterizes the 
glucose uptake of the peripheral insulin-sensitive tissues.21
Derivative measures regarding the characterization of the 
insulin action can be calculated by means of plasma insulin 
and blood glucose values obtained during the fasting state 
as well during as the steady state of the HEGC. Accordingly, 
the insulin sensitivity of the peripheral tissues was character-
ized by the insulin sensitivity index (ISI), a measure of the 
amount of glucose taken up by peripheral tissues per unit of 
plasma insulin concentration.22 Furthermore, the metabolic 
clearance rate of insulin (MCRI) as an indicator of the rate 
of disappearance of insulin from the blood was calculated as 
the insulin infusion rate (mU/kg/minute), divided by the dif-
ference between the steady-state and fasting-plasma insulin 
level, and was expressed as mL/kg/minute.22
Statistical analysis
All data were expressed as mean ± standard deviation (SD) 
and were analyzed with paired t-tests when possible; other-
wise, one-way analysis of variance followed by a modified 
repeated measures t-test (according to Bonferroni’s method) 
was used.23
Results
One-dimensional DPM
The basis of the oDPM analysis is that the pairwise similari-
ties between two IPs were considered as vectors in a multidi-
mensional space (Figure 1A). This approach is referred to as 
“one-dimensional” since the distance of the two IP vectors is 
a one-dimensional measure. The advantage of this measure 
is that it reflects the pattern of the docking score values in 
the profile more than the actual scores. For instance, if two 
drugs possess the same IP, but with different average dock-
ing scores, their d value will be small, suggesting a high 
level of similarity. On the other hand, a single miscalculated 
docking score can cause significant error in the distance 
 measurement. This disadvantage is eliminated in DPM.2 It 
should be mentioned that in the case of small groups (less 
than ten members), DPM cannot be applied because of the 
high probability of overfitting.2 Therefore, PPARγ predic-
tions can be obtained only by a simpler method like oDPM, 
regardless of its generally weaker prediction accuracy when 
compared to DPM. The average area under the curve value 
of oDPM on 157 effect groups with at least ten members is 
0.62 ± 0.12, while the accuracy of DPM is 0.97 ± 0.03.3
After examining the closest neighbors of the members 
of the reference set, and after counting the most abundant 
neighbors of the members, ten generic drugs were selected if 
they appeared on the list three times: dantrolene, entacapone, 
ethacrynic acid, ketorolac, tiaprofenic acid, tolmetin, bro-
mfenac, lubiprostone, nitazoxanide, and suprofen (Table 1). 
A further 44 compounds appeared on the list twice, while 116 
drugs reached one appearance; all of them were discarded. 
The IP distance value matrix of these ten compounds is dis-
played in Table 2. It is notable that the compounds are close 
to each other and seem to form a fairly coherent group that 
is similar to the reference set (average IP distance values and 
standard errors for the reference set and the predicted set are 
1.37 ± 0.85 and 1.30 ± 0.77, respectively). Lubiprostone is 
the only compound that is distant from the others. Based on 
these results, no further refinement of the prediction could 
be performed; therefore, these ten compounds were piped 
to in vitro screening.
In vitro study, the effect on FABP4/aP2 
gene activity
Six of the ten chemical structures studied (Table 1) did not 
alter FABP4/aP2 gene expression in the MM6 cell line (data 
not shown). On the other hand, bromfenac, nitazoxanide, 
suprofen, and lubiprostone induced significant elevation in 
the FABP4/aP2 gene transcript (Figure 2A–D).  However, 
the induced elevation in the mRNA expression was  distinct 
among the MM6 cell lines treated with these four  chemicals. 
Suprofen induced a significant elevation in the mRNA 
expression level, though at its lowest concentration applied 
(10−8 M); however, increasing doses were not followed 
by further elevation in mRNA expression, except at its 
highest dose (10−5 M), but this change was not significant 
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Table 1 Generic drugs showing PPARγ receptor ligand affinity after the One-dimensional Drug Profile Matching screening
Bromfenac Dantrolene Entacapone Ethacrynic acid Ketorolac
Nonsteroidal  
anti-inflammatory drug
Ryanodine receptor  
antagonist
Catechol-O-methyl  
transferase inhibitor
Na+-K+-Cl− cotransport  
inhibitor
Nonsteroidal  
anti-inflammatory drug
Lubiprostone Nitazoxanide Suprofen Tiaprofenic acid Tolmetin
PGE1 analogue,  
activates CIC-2  
chloride channels
Antiprotozoal agent,  
interfere with the  
electron transfer
Nonsteroidal  
anti-inflammatory  
drug
Nonsteroidal  
anti-inflammatory drug
Nonsteroidal  
anti-inflammatory 
drug
Notes: Detailed description of the selection is described in the text. The original, known pharmacological action/indication of these drugs is also indicated.
Abbreviations: PGE1, prostaglandin E1; CIC-2, chloride channel.
compared to its lower doses. Lubiprostone also induced 
significant elevation in the mRNA level at its lowest dose 
(10−8 M) applied; however, the effect induced by increasing 
its doses was inconsistent, and no dose-dependent eleva-
tion in mRNA expression was seen. The other two drugs, 
bromfenac and nitazoxanide, induced dose-dependent 
activation of the FABP4/aP2 gene. Bromfenac caused sig-
nificant elevations in mRNA expression in the two higher 
doses (10−6 M and 10−5 M), while the nitazoxanide was able 
to induce significant elevation in 10−7 M concentration, and 
its effect seemed to be dose-dependent in that its effect on 
FABP4/aP2 gene activity was nonsignificant in the 10−6 M 
concentration. The greater SD can explain the observed 
nonsignificant alteration.
The percentile changes in FABP4/aP2 gene expression 
were also determined by comparing the effects of the highest 
applied dose of these four drugs to the effects elicited by their 
vehicle. In this comparison, lubiprostone proved to be the 
most effective, showing an approximate 10 times elevation in 
the normalized mRNA expression level, while nitazoxanide, 
suprofen and bromfenac showed 7 times, 6 times and 3 times 
elevation, respectively (Figure 3).
Rosiglitazone as a reference drug induced a concentra-
tion-dependent enhancement in FABP4/aP2 gene expression 
in the MM6 cell line. Moreover, the stimulating effect of 
rosiglitazone on FABP4/aP2 gene expression was approxi-
mately one order of magnitude higher than that observed 
after administration of either of the other drugs (data not 
shown). On the other hand, the vehicles failed to evoke any 
changes in FABP4/aP2 gene expression in the MM6 cell line 
(data not shown).
In vivo study, determination of whole-
body insulin sensitivity
Based on the in vitro data and the available information 
regarding these generic drugs, we selected nitazoxanide for 
further study in order to determine its insulin sensitizing 
effect on type 2 diabetic rats.
The effect of different treatment schedules on the glyce-
mic control of different groups of rats has been summarized 
in Figure 4 and Table 3. Animals held on a HFD became 
insulin resistant, but not diabetic at the end of the 3-week diet 
period. Rats treated with intravenous STZ at the end of the 
second week of the HFD regimen showed not only decreased 
insulin sensitivity compared to healthy animals, but also 
marked fasting hyperglycemia (ie, these rats became type 2 
diabetic). The vehicle-treated healthy and HFD groups of rats 
showed significantly lower fasting blood glucose levels and 
significantly elevated GIR and ISI compared to the vehicle-
treated HFD + STZ rats. The nitazoxanide treatment induced 
a dose-dependent improvement in the glycemic status of 
the HFD + STZ-treated type 2 diabetic rats. This improve-
ment in glycemic status was characterized by a significant 
increase in the GIR needed to maintain euglycemia, as well 
as by the enhancement of the ISI during the HEGC in rats 
treated with 200 mg/kg nitazoxanide over 8 days. The fasting 
blood glucose level of the vehicle-treated HFD + STZ rats 
was significantly elevated compared to the vehicle-treated 
healthy or HFD rats, and nitazoxanide treatment showed a 
dose-dependent reduction in the fasting blood glucose level, 
reaching a statistically significant level at a dose of 200 mg/
kg. The fasting plasma insulin level was elevated in all 
type 2 diabetic groups (HFD + STZ + vehicle, HFD + STZ 
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d + nitazoxanide) and the nitazoxanide treatment did not cause 
a significant change. Finally, no significant difference among 
the MCRI could be observed in either treatment groups. In 
addition, no alteration in the resting mean arterial blood 
pressure was observed (Figure 4 and Table 3).
Discussion
The aim of the present study was to find generic drug(s) 
with PPARγ receptor agonist activity by means of screening 
the FDA-approved generic molecule database using oDPM 
methods. As a result of our current work, we have identified 
ten potential PPARγ ligands by means of the oDPM method. 
It had been shown that four out of the selected ten drugs were 
able to induce the expression of the transcript of the FABP4/
aP2 gene, which is specific to PPARγ receptor activation. 
Among these four generics, nitazoxanide was chosen to 
further study its putative PPARγ receptor agonist action by 
means of HEGC in a rodent model of type 2 diabetes in order 
to explore its insulin sensitizing property.18,21
The drug development process became very expensive 
during the last decades. There have been several attempts 
made, trying to shorten the time-to-market as well as to 
decrease the amount of human and financial resources 
needed for the drug development process. In order to solve 
these above mentioned difficulties, the interest of the phar-
maceutical industry has turned to the renewal of generics. 
Using drugs at the same or lower concentrations, as well as 
for similar treatment periods as were used in their original 
indications, several steps in the development process can 
be spared, such as conducting time-consuming and costly 
toxicity studies; an example of this kind of drug renewal was 
published previously.24 We demonstrated that cicletanine, a 
phosphodiesterase enzyme 1–5 inhibitor (originally devel-
oped for the treatment of hypertension), is able to enhance 
whole-body insulin sensitivity in insulin-resistant rabbits at 
lower doses than is required for its vascular effects.24
The actuality of our present study has been underpinned 
by the fact that the prevalence of diabetes is increasing 
globally, and the total number of patients suffering from this 
chronically devastating condition have reached 347 million.25 
On the other hand, the number of available drugs used to 
treat diabetes is limited, and the most frequently prescribed 
medications are thiazolidinediones, which have several 
side effects such as fluid retention, edema, congestive heart 
failure, or bone fractures.26–28 Although these side effects are 
due to the activation of the PPARγ receptor, conformation 
of the receptor is the key feature that determines the affin-
ity of corepressors and coactivators to the ligand-bound 
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Figure 2 The effect of (A) bromfenac, (B) nitazoxanide, (C) suprofen, and (D) lubiprostone (10−8 M to 10−5 M) on FABP4/aP2 gene expression in MM6 cell lines. Rosiglitazone 
(10−8 M to 10−6 M) was used as a positive control. *Indicates significant changes from the vehicle-treated (DMSO or ethanol) control.
Abbreviations: RNA, ribonucleic acid; DMSO, dimethyl sulfoxide; FABP4/ap2, fatty acid-binding protein 4/adipocyte protein; MM6, Mono Mac 6.
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Table 3 The effect of 8-day nitazoxanide treatment (50 mg/kg/day, 100 mg/kg/day, and 200 mg/kg/day) on the fasting blood glucose 
and plasma insulin level, on the resting blood pressure, as well as on body weight
Fasting blood glucose 
(mmol/L)
Fasting plasma insulin 
(μIU/mL)
Mean arterial blood pressure 
(mm Hg)
Body weight 
(g)
Health, vehicle 4.3 ± 0.3* 5.8 ± 0.4* 124 ± 11 341 ± 22
HFD, vehicle 4.37 ± 0.7* 5.3 ± 0.3* 129 ± 12 384 ± 26
HFD + STZ, vehicle 8.7 ± 1.3 17.5 ± 5.5 129 ± 8 345 ± 35
HFD + STZ + NTX 50 mg/kg 8.5 ± 1.5 14.3 ± 4.7 122 ± 12 366 ± 21
HFD + STZ + NTX 100 mg/kg 8.1 ± 1.4 17.2 ± 4.4 126 ± 13 372 ± 33
HFD + STZ + NTX 200 mg/kg 7.3 ± 1.2* 18.7 ± 5.2 127 ± 10 370 ± 30
Note: *Indicates significant changes from the HFD + STZ and vehicle-treated groups.
Abbreviations: HFD, high-fat diet; STZ, streptozotocin; NTX, nitazoxanide.
PPARγ receptor, thereby determining the gene transcription 
profile and biological response after PPARγ activation.29,30 
The diverse regulation of the PPARγ  receptor activation and 
signal transduction pathways was made  feasible to design 
selective PPARγ modulator molecules, which retain the 
insulin-sensitizing effect, but do not possess those unwanted 
effects mentioned above.30
In the present study, we used computational model-
ing of the receptor–ligand interaction, which ensures high 
throughput screening of large molecule libraries. By screen-
ing the FDA-approved generics molecule database, our 
results supported the original assumption that the in silico 
oDPM methodology applied could facilitate the initial drug 
candidate selection if the molecular structure of the target 
protein is known. Here we combined the advantages of the in 
silico oDPM method and generics-based drug development 
strategy. The in silico oDPM method used allows us to select 
candidates from the molecule library within a relatively short 
time period. Using generics in new therapeutic indication 
could shorten the development process. On the other hand, 
the in silico prediction method has some  limitations. For 
example, it does not allow us to establish whether the estab-
lished receptor–ligand interaction corresponds to agonist 
or antagonist properties on the targeted receptor. In order 
to answer this important question, both in vitro and in vivo 
experiments were carried out.
oDPM was incapable of finding any differences between 
the four compounds that were active in vivo, and the rest of 
the predicted set, which again underlines the importance of 
in vitro testing and reminds us of the inherent limitations of 
in silico approaches. Our oDPM method is also currently 
incapable of predicting the side effects of a compound. 
Side effect prediction is more difficult than the presented 
prediction process, since the side effect databases are often 
incomplete and a lot of questions need to be answered (ie, 
the ambiguous terminology of the adverse events, the han-
dling of different frequencies of adverse events depending 
on the exact treatment and dosage, and so on). Of course, 
the list of the effects and targets of the close IP neighbors of 
a molecule might still yield clues to its potential side effects 
(for example, a predicted angiotensin-converting enzyme 
inhibitory effect can point to possible effects on blood pres-
sure). This opportunity will be addressed in future research, 
using the DPM method because it performs better than oDPM 
when studying large groups.
The data from in vitro experiments revealed those 
generics from our selection list that are able to stimulate the 
PPARγ receptor in a dose-dependent manner. Finally, in vivo 
experiments were carried out in order to study whether PPARγ 
activation results in the enhancement of insulin sensitivity 
among insulin-resistant, type 2 diabetic rats. Whole-body 
insulin sensitivity was determined by means of HEGC, the 
gold standard for determining insulin sensitivity in humans.21 
Since the full insulin-sensitizing effect of PPARγ receptor 
activation requires several days, we treated the animals for 
8 days, which has been shown to be sufficient in inducing 
insulin-sensitizing effects in rodents.31,32
According to our original concept, we intended to 
investigate the putative insulin sensitizing action of the 
selected generics using the same dose-range as was used in 
its original indication. In the present study, we investigated 
the insulin-sensitizing effect of nitazoxanide, a generic drug 
that was originally approved as an antiprotozoal agent. Its 
established mechanism of action is to inhibit the pyruvate 
ferredoxin oxidoreductase enzyme-dependent electron 
transfer  reaction.33 Beside on its antiprotozoal action, the 
experimental results suggested that nitazoxanide can also 
bear antiviral activity due to its blocking properties over the 
maturation of the viral hemagglutinin, which in turn results 
in impaired intracellular trafficking and insertion into the 
host plasma membrane of the hemagglutinin.34 On the other 
hand no data regarding its putative PPARγ receptor-activating 
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action are available in the literature or in the patent databases. 
In an immunosuppressed rat model of cryptosporidiosis, nita-
zoxanide was able to effectively inhibit the oocyte shedding 
at a daily oral dose of 50–200 mg/kg.19 So, we selected this 
same dose range and the applied treatment lasted for 8 days, 
according to the time required for evolution of the effect of 
PPARγ  activation. Although in clinical practice nitazoxanide 
is usually administered for only 3–5 days to treat protozoal 
infections, the available preclinical toxicological data sug-
gest that there are no safety concerns when nitazoxanide is 
used for a longer term.35 These features made nitazoxanide 
an ideal generic drug candidate to be reintroduced in a new 
clinical indication as an insulin-sensitizing agent.
The main discovery of the present study is the dem-
onstration of the predictive value of the oDPM method in 
searching for PPARγ ligands. The positive predictive value 
of the oDPM method was supported both by in vitro mea-
surement of FABP4/aP2 gene activity after dose-dependent 
exposure of the MM6 cell line to nitazoxanide, and by in vivo 
 demonstration of the dose-dependent insulin-sensitizing effect 
of nitazoxanide using an insulin-resistant type 2 diabetic rat 
model. Although we did not determine PPARγ mRNA or 
protein expression from the tissue samples after the in vivo 
experiments, our results did suggest that the improvement in 
insulin sensitivity could be a consequence of the enhance-
ment in the glucose uptake of the peripheral insulin-sensitive 
tissues, since both the GIR and the ISI were increased in 
response to nitazoxanide treatment. On the other hand, the 
MCRI and the steady-state plasma insulin level were left 
unaffected by the nitazoxanide treatment. These data indicate 
that the putative mechanism of action of nitazoxanide is in 
the enhancement of the insulin sensitivity, which is similar to 
what was expected after PPARγ stimulation. Moreover, our 
results demonstrated that nitazoxanide failed to induce body 
weight gain and elevation in mean arterial blood pressure. It 
should be noted that the treatment period was only 8 days, and 
thus changes in either weight gain or systemic blood pressure 
cannot be ruled out, as they may occur after longer treatment 
periods. A more comprehensive study investigating the effects 
of the chronic administration of nitazoxanide on different 
organ systems will be able to address this issue.
Conclusion
Taken together, our results demonstrate the usefulness of 
the oDPM method in the screening of a molecule database 
for lead selection, and we discovered and supported the 
insulin-sensitizing effect of nitazoxanide, a generic anti-
protozoal drug, in both in vivo and in vitro experiments. 
Using this technology, pharmaceutical companies can 
speed up the otherwise costly and time-consuming drug 
development process.
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